Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Labs

CRANFORD, N.J., Sept. 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd.

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Bridgeline Digital

Kosmos Energy

With September only a day away, which penny stocks are on your buy list? The post Best Penny Stocks For Your Buy List in September?

Best Penny Stocks For Your Buy List in September? 3 To Watch

CRANFORD, N.J., Aug. 12, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today reported financial results for the third fiscal quarter of 2021 ended June 30, 2021, and provided a general business update.

Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update

Image by falco from Pixabay What happens when the one product keeping you alive becomes infected?

Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs

Endo International

There's a reason that so many investors like Reddit penny stocks; here's 3 for your list The post Best Reddit Penny Stocks to Buy in August? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Reddit Penny Stocks to Buy in August? 3 For Your List

A lot would have to go right for this biotech to make investors rich.

Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?

Color Star Technology

China Rapid Finance

These Reddit Penny Stocks Are Rising in Popularity Right Now; Are They Worth It or Not? The post 3 Penny Stocks That Are Popular With Reddit Traders Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Are Popular With Reddit Traders Right Now

Annovis Bio

Brooklyn ImmunoTherapeutics

Jazz Pharmaceuticals

Mind Medicine MindMed

Cassava Sciences Inc

SpringWorks Therapeutics Inc

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Companies to Invest In for July

NEW YORK, July 7, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Citius Pharmaceuticals, Inc. ("Citrus" or the "Company") (NASDAQ: CTXR).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Citius Pharmaceuticals, Inc. - CTXR

Vinco Ventures

Diffusion Pharmaceuticals

Powerbridge Technologies Co Ltd

Seanergy Maritime Hlds

Vivos Therapeutics

Weidai Ltd - ADR

Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?

Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021

CRANFORD, N.J., July 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today provided a business update for the six-month period ended June 30, 2021 and reported on recent corporate developments.

Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones

Investors need to pay close attention to Citius Pharmaceuticals (CTXR) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Citius Pharmaceuticals (CTXR) Stock?

Another interim analysis has come and gone with an unsatisfying result.

Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today

CRANFORD, N.J., July 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that following a unblinded data review of safety and efficacy, the independent Data Monitoring Committee (DMC) for the Mino-Lok® Phase 3 Pivotal Superiority Trial has recommended proceeding with the trial as planned.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

American Battery Technology Company

Nokia

Transocean

SNDL Inc.

Timber Pharmaceuticals

If we've learned anything from the Reddit in January, it's not to underestimate them. These 7 Reddit penny stocks have good upsides.

7 Reddit Penny Stocks to Watch for Big Upside Ahead

In a world facing a global pandemic, advancements in the healthcare sector are pivotal, especially with unmet medical needs of different ranges of diseases and at different levels. From traditional names like Merck & Co. (NYSE: MRK), Pfizer, Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Abbott Laboratories (NYSE: ABT) to innovative new companies like Biotricity Inc. (OTC: BTCY) and Lexaria Bioscience Corp. (NASDAQ: LEXX), among others, many are stepping up their game.

Citius Shows a Promising Future as Share Prices Keep Going up

See if this biotech has what takes to climb even higher.

Is It Too Late to Buy Citius Pharmaceuticals Stock?

Luokung Technology Corp

Looking for penny stocks to buy in July 2021? Check these 3 for your watchlist The post Which Penny Stocks Are the Best to Buy Right Now?

Which Penny Stocks Are the Best to Buy Right Now? 3 to Watch in 2021

Best Penny Stocks to Watch in Summer 2021 With Summer upon us, which penny stocks are investors buying right now? Well, there are quite a few answers to this question.

Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist

The stock price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) increased by over 10% during intraday trading. This is why it happened.

CTXR Stock Price Increases Over 10%: Why It Happened

IDMC meets on June 29 for Superiority review. Mino-Lok has no competition.

Citius: Halt For Superiority On The Horizon

CRANFORD, N.J., June 15, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board (SAB), effective immediately.

Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS

Asensus Surgical

Atossa Genetics

GT Biopharma Inc

If biotech penny stocks are your focus, check these 4 out right now The post 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021

CRANFORD, N.J., June 8, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that the next planned interim analysis in its Phase 3 trial of Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related blood stream infections (CRBSIs/CLABSIs) has been scheduled for the end of June 2021.

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

CRANFORD, N.J., June 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.

Citius Pharmaceuticals to be Added to Russell 2000® Index

News for Citius Pharmaceuticals Stock (CTXR)